Skip to content
Screener

Total Liabilities at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65.32B-15.4%
Supernus Pharmaceuticals logo
Supernus PharmaceuticalsSUPN
$206K-99.9%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$53.38M+32.4%
Praxis Precision Medicines, Inc. logo
Praxis Precision Medicines, Inc.PRAX
$49.06M+0.9%
Biohaven logo
BiohavenBHVN
$336.91M+68.9%
Septerna, Inc. logo
Septerna, Inc.SEPN
$180.02M+378%

Other financials

Income statement

See full
Revenue-
Operating income-$60.8M-106%
Net income-$56.6M-112%
EPS (diluted)-$1.19-58.7%

Balance sheet

See full
Cash & equivalents$63.6M+15.5%
Total debt$10.1M-14.8%
Total equity$422.9M+60.5%
Total assets$459.0M+60.8%

Cash flow

See full
Operating cash flow-$41.5M-65.4%
CapEx$78.0K+255%
Free cash flow-$41.5M-65.5%

Valuation

See full
Market cap$2.25B+332%
Enterprise value$2.2B+360%
P/S112.7×

Profitability

See full
Operating margin-767.6%
Net margin-685.8%
FCF margin-485.7%

Returns & leverage

See full
Return on equity-40%+22.3pp
Debt / equity0.0×
Current ratio15.7×-7.0×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:30 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333862
Line itemJune 30,2026December 31,2025
Operating lease liability2,4732,755
Total current liabilities28,42419,049
Operating lease liability, net of current portion7,6328,729
Total liabilities36,05627,778
Commitments and contingencies (Note 10)
Stockholders’ equity
Undesignated preferred stock, $0.001 par value; 10,000,000 shares authorized at June 30, 2026 and December 31, 2025, respectively; zero shares issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 500,000,000 shares authorized at June 30, 2026 and December 31, 2025; 47,955,079 shares and 47,772,567 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively4848

Item 1. Financial Statements.

FAQ

What is Rapport Therapeutics, Inc.'s total liabilities?
Rapport Therapeutics, Inc. (RAPP) reported total liabilities of $36.06M in Q2 2026.
How has Rapport Therapeutics, Inc.'s total liabilities changed year-over-year?
Rapport Therapeutics, Inc.'s total liabilities increased by 64.0% year-over-year, from $21.98M to $36.06M.
What is the long-term trend for Rapport Therapeutics, Inc.'s total liabilities?
Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s total liabilities has grown at a 38.5% compound annual growth rate (CAGR), from $14.48M to $27.78M.
What does total liabilities mean?
The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.

Ask your AI about Rapport Therapeutics, Inc.'s total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude